Today: 29 April 2026
Browse Category

NASDAQ:NVAX 6 November 2025 - 31 January 2026

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax (NASDAQ: NVAX) closed at $6.91 on December 5, 2025, with a market cap near $1.1 billion. Shares are down about 20% over the past year and 94% over five years. Q2 2025 saw a surprise profit on $239 million revenue, boosted by a $175 million Sanofi milestone payment, but Q3 revenue dropped to $70 million with a net loss of $202 million. The stock trades 40% below its January high.
7 December 2025
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NASDAQ: NVAX) closed at $6.47 on Friday, up 4.0% but still 44% below its 52-week high. Q3 revenue beat estimates at $70 million, though losses widened and profitability is now targeted for 2028. Shah Capital is pressuring for a sale and threatening a proxy fight. The company expanded its Sanofi partnership, securing $225 million in milestones this year.
24 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····

Stock Market Today

  • Tuya (TUYA) Stock Analysis: Fair Pricing Amid Recent Pullback and Strong Long-Term Gains
    April 29, 2026, 12:05 PM EDT. Tuya (NYSE:TUYA) shares closed at $2.28, down 3.0% in one day and 6.2% over seven days, contrasting with a 3-year total shareholder return of 28.7%. The company reported $321.8 million in annual revenue and $57.9 million net income. Trading at a price-to-earnings (P/E) ratio of 24.1x, Tuya's valuation is slightly above its fair value estimate of 23.5x and peers' average of 21.7x, but below the broader U.S. Software industry average of 30.4x. This reflects investor confidence in its profitability and growth prospects, with earnings expected to grow nearly 10% annually. Risks include dependence on Chinese market demand and relatively rich valuation compared to peers. The stock trades just 0.9% below its intrinsic value according to discounted cash flow (DCF) estimates, suggesting near fair pricing.

Latest article

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

29 April 2026
Purchase, New York, April 29, 2026, 12:06 EDT Mastercard shares rose 3.8% to $526.90 in late Wednesday morning trading, as investors marked up payment networks after Visa beat profit estimates and raised its full-year earnings outlook a day before Mastercard reports its own quarter. Visa shares were up 8.7%, while American Express was little changed. (Reuters) The move matters because Mastercard’s Thursday report will give investors another quick read on whether card spending is still holding up despite higher costs, war-driven travel disruption and broader market caution. Mastercard said it will release first-quarter results on April 30 and hold a
GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

29 April 2026
GE HealthCare cut its 2026 profit forecast Wednesday, citing higher chip, oil, and freight costs, as well as tariffs and a supplier issue. Shares fell nearly 13% to $59.75. First-quarter revenue rose 7.4% to $5.13 billion, but net income dropped to $389 million from $564 million a year earlier. The company also announced a reorganization, merging its Imaging and Advanced Visualization units.
Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

29 April 2026
The U.S. Commerce Department ordered Applied Materials, Lam Research, and KLA to halt some chip-tool shipments to China’s Hua Hong, Reuters reported. The move targets shipments linked to facilities believed capable of advanced chip production. Applied reported $2.10 billion in China revenue last quarter, or 30% of its total. Shares in Applied, Lam, and KLA traded lower after the news.
Go toTop